 About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM Catalog
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
|
|
-
Selective serotonin
reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by
different mechanisms.
Yamada J, Sugimoto Y, Inoue
K.
Department of Pharmacology, Kobe Pharmaceutical
University, Motoyamakita-machi, Higashinada-ku, Kobe, Japan.
j-yamada@kobepharma-u.ac.jp
The effects of the selective
serotonin reuptake inhibitors, fluoxetine and fluvoxamine, on plasma
glucose levels were investigated in mice. Both fluoxetine and
fluvoxamine elicited significant hyperglycemia, while a selective
noradrenaline reuptake inhibitor maprotiline had no effect. Fluoxetine
and fluvoxamine did not change serum insulin levels, although they
elicited hyperglycemia. Pretreatment with the serotonin
(5-hydroxytryptamine, 5-HT) depleter, p-chlorophenylalanine (pCPA),
abolished fluvoxamine-induced hyperglycemia, although pCPA did not
affect the fluoxetine-induced glycemic effects. These results suggest
that the selective serotonin reuptake inhibitors fluoxetine and
fluvoxamine induce hyperglycemia by inhibition of insulin release.
Moreover, our findings indicate that the glycemic effects of these drugs
are differentially associated with serotonergic mechanisms.
PMID:
10556672 [PubMed - indexed for MEDLINE]
|